Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling
Open Access
- 14 April 2020
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-15
Abstract
The hexosamine biosynthetic pathway (HBP) plays critical roles in nutrient sensing, stress response, and cell growth. However, its contribution to cardiac hypertrophic growth and heart failure remains incompletely understood. Here, we show that the HBP is induced in cardiomyocytes during hypertrophic growth. Overexpression of Gfat1 (glutamine:fructose-6-phosphate amidotransferase 1), the rate-limiting enzyme of HBP, promotes cardiomyocyte growth. On the other hand, Gfat1 inhibition significantly blunts phenylephrine-induced hypertrophic growth in cultured cardiomyocytes. Moreover, cardiac-specific overexpression of Gfat1 exacerbates pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction. Conversely, deletion of Gfat1 in cardiomyocytes attenuates pathological cardiac remodeling in response to pressure overload. Mechanistically, persistent upregulation of the HBP triggers decompensated hypertrophy through activation of mTOR while Gfat1 deficiency shows cardioprotection and a concomitant decrease in mTOR activity. Taken together, our results reveal that chronic upregulation of the HBP under hemodynamic stress induces pathological cardiac hypertrophy and heart failure through persistent activation of mTOR.Keywords
Funding Information
- American Heart Association (17IRG33460191)
- American Diabetes Association (1-17-IBS-120)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL137723)
This publication has 56 references indexed in Scilit:
- Glucose Regulation of Load‐Induced mTOR Signaling and ER Stress in Mammalian HeartJournal of the American Heart Association, 2013
- The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolismJournal of Clinical Investigation, 2012
- The roles ofO-linked β-N-acetylglucosamine in cardiovascular physiology and diseaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Variable phenotype in murine transverse aortic constrictionCardiovascular Pathology, 2012
- Targeting Myocardial Substrate Metabolism in Heart Failure: Potential for New TherapiesEuropean Journal of Heart Failure, 2012
- O-GlcNAc signalling: implications for cancer cell biologyNature Reviews Cancer, 2011
- Cross Talk Between O-GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic DiseaseAnnual Review of Biochemistry, 2011
- The hexosamine signaling pathway: O-GlcNAc cycling in feast or famineBiochimica et Biophysica Acta (BBA) - General Subjects, 2010
- Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2American Journal of Physiology-Cell Physiology, 2008
- Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heartCardiovascular Research, 2007